Zentalis Pharmaceuticals Llc (ZNTL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $157.22M
Last updated: Nov 17, 2026 at 4:23 PM ET
Zentalis Pharmaceuticals Llc (ZNTL) Statistics
Zentalis Pharmaceuticals Llc (ZNTL) has a market cap of $157.22M and an enterprise value of $133.20M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 17.29% from a year earlier.
Total Valuation
Enterprise value is 15.28% below the market cap, as cash exceeds debt.
| Market Cap | $157.22M |
|---|---|
| Enterprise Value | $133.20M |
| Latest price (Nov 17, 2026) | $1.49 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 12.03% over 52 weeks and trades 38.68% below its 50-day average.
| Beta (1Y) | 1.82 |
|---|---|
| 52-Week Change | +12.03% |
| 1-Month Change | -35.22% |
| 3-Month Change | -60.99% |
| 6-Month Change | -57.91% |
| 5-Year Change | -97.56% |
| Total Return (1Y) | +12.03% |
| Total Return (3Y CAGR) | -49.17% |
| Total Return (5Y CAGR) | -54.82% |
| Return vs SPY (1Y) | -2.00% |
| Max Drawdown (1Y) | -77.46% |
| Max Drawdown (3Y) | -93.69% |
| Sharpe Ratio (1Y) | 0.08 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $2.43 |
| 200-Day Average | $3.39 |
| 52-Week Range | $1.28 to $6.95 |
| RSI (14 Days) | 26.7 |
| Average Volume (20 Days) | 1.40M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.33x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.33x |
|---|---|
| Quick Ratio | 7.33x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -69.14% over the last 12 months, against a 5-year average of -55.95%.
| Return on Equity (ROE) | -69.14% |
|---|---|
| Return on Assets (ROA) | -52.43% |
| ROE (5Y Average) | -55.95% |
| ROA (5Y Average) | -43.89% |
| ROIC (5Y Average) | -63.19% |
Scores
ZNTL has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$157.00K |
| Operating Income | -$150.79M |
| Pretax Income | -$140.85M |
| Net Income | -$141.67M |
| Reported EPS (TTM) | -$1.92 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.83% of the $270.19M in total assets.
| Cash and Equivalents | $24.03M |
|---|---|
| Total Debt | $0 |
| Net Cash | $24.03M |
| Net Cash Per Share | $0.28 |
| Working Capital | $204.91M |
| Shareholder Equity | $204.89M |
| Book Value Per Share | $2.42 |
| Total Assets | $270.19M |
| Total Liabilities | $65.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$133.84M |
|---|---|
| FCF Per Share | -$1.36 |
| Depreciation and Amortization | $1.47M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -30.13% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -29.83% |
Dividends and Yields
ZNTL does not pay a dividend.
| Buyback Yield | -73.80% |
|---|---|
| Shareholder Yield | -73.80% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ZNTL
What is ZNTL's market cap?
Zentalis Pharmaceuticals Llc has a market cap of $157.22M. Its enterprise value, which adds debt and subtracts cash, is $133.20M.
How many shares of ZNTL are outstanding?
Zentalis Pharmaceuticals Llc has 84.61M shares outstanding. The count is up 17.29% from a year earlier.
Does ZNTL pay a dividend?
No. Zentalis Pharmaceuticals Llc does not pay a dividend.
How much debt does ZNTL have?
Zentalis Pharmaceuticals Llc has $0 of total debt and $24.03M of cash and equivalents, a net cash position of $24.03M.
ZNTL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors